Medtronic PLCMDT
▲ PositiveCapitalrelevance
Analysts expect strong Q1 earnings growth with upward estimate revisions, and management guidance indicates solid growth.
Impact on stocks 1
Robotics & Physical AI
Medtronic PLCMedtronic is scheduled to announce its fiscal first-quarter earnings on September 1 after markets close, with analysts expecting strong growth. The consensus EPS estimate is $1.39, a 10.3% year-over-year increase, while revenue is expected to rise 12.2% to $9.54 billion. Over the past three months, EPS estimates have seen 11 upward revisions and 7 downward moves, while revenue estimates have seen 15 upward and 4 downward adjustments, indicating bullish sentiment. Management guided first-quarter organic revenue growth between 11.5% and 12%, and full-year growth of 6.75% to 7.25%, with fiscal 2027 earnings in the range of $5.90 to $6.00. The company also anticipates a tariff impact on cost of goods sold of $75 million in the first quarter, leading to an annual impact of $250 million. Analysts will focus on the performance of its cardiac ablation solutions, which surged 78% year-over-year globally last quarter, and on any revisions to guidance and the timing of the MiniMed disposal.
Medtronic PLCAnalysts expect strong Q1 earnings growth with upward estimate revisions, and management guidance indicates solid growth.